Literature DB >> 16250030

Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics.

Denise M Kay1, Cyrus P Zabetian, Stewart A Factor, John G Nutt, Ali Samii, Alida Griffith, Tom D Bird, Patricia Kramer, Donald S Higgins, Haydeh Payami.   

Abstract

The G2019S mutation in the LRRK2 gene is reportedly a common cause of familial Parkinson's disease (PD) and may also have a significant role in nonfamilial PD. The objective of this study was to assess mutation carrier frequency in PD patients from movement disorder clinics in the United States, stratified by family history, age at onset, and geography; to determine carrier frequency in a large and well-characterized control population; to examine segregation of mutation in families of patients; and to correlate genotype with clinical phenotype. One thousand four hundred twenty-five unrelated PD patients from movement disorder clinics in Oregon, Washington, and New York and 1,647 unrelated controls were studied. The G2019S mutation was detected using a TaqMan assay and verified by sequencing. Eighteen of 1,425 patients and one of 1,647 controls had the mutation. Carrier frequency (+/- 2SE) in patients was 0.013 +/- 0.006 overall, 0.030 +/- 0.019 in familial PD, 0.007 +/- 0.005 in nonfamilial PD, 0.016 +/- 0.013 in early-onset PD, and 0.012 +/- 0.007 in late-onset PD. Geographic differences were insignificant. Age at onset of mutation carriers ranged from 28 to 71 years. Mutation carriers were clinically indistinguishable from idiopathic PD. LRRK2 G2019S is the single most common pathogenic mutation linked to neurodegenerative disease to date. Copyright 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16250030     DOI: 10.1002/mds.20751

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  32 in total

1.  Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene.

Authors:  Xiao-Xia Li; Qin Liao; Huan Xia; Xin-Ling Yang
Journal:  Exp Ther Med       Date:  2015-07-27       Impact factor: 2.447

2.  Analysis of the LRRK2 G2019S mutation in Alzheimer Disease.

Authors:  Cyrus P Zabetian; Chris J Lauricella; Debby W Tsuang; James B Leverenz; Gerard D Schellenberg; Haydeh Payami
Journal:  Arch Neurol       Date:  2006-01

3.  Autophagy in neurite injury and neurodegeneration: in vitro and in vivo models.

Authors:  Charleen T Chu; Edward D Plowey; Ruben K Dagda; Robert W Hickey; Salvatore J Cherra; Robert S B Clark
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

Review 4.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

5.  Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.

Authors:  Stewart A Factor; N Kyle Steenland; Donald S Higgins; Eric S Molho; Denise M Kay; Jennifer Montimurro; Ami R Rosen; Cyrus P Zabetian; Haydeh Payami
Journal:  Mov Disord       Date:  2011-06-28       Impact factor: 10.338

6.  Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.

Authors:  Gaia Skibinski; Ken Nakamura; Mark R Cookson; Steven Finkbeiner
Journal:  J Neurosci       Date:  2014-01-08       Impact factor: 6.167

Review 7.  PARK8 LRRK2 parkinsonism.

Authors:  Kristoffer Haugarvoll; Zbigniew K Wszolek
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

8.  LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.

Authors:  Cyrus P Zabetian; Carolyn M Hutter; Dora Yearout; Alexis N Lopez; Stewart A Factor; Alida Griffith; Berta C Leis; Thomas D Bird; John G Nutt; Donald S Higgins; John W Roberts; Denise M Kay; Karen L Edwards; Ali Samii; Haydeh Payami
Journal:  Am J Hum Genet       Date:  2006-08-17       Impact factor: 11.025

9.  Screening for replication of genome-wide SNP associations in sporadic ALS.

Authors:  Simon Cronin; Barbara Tomik; Daniel G Bradley; Agnieszka Slowik; Orla Hardiman
Journal:  Eur J Hum Genet       Date:  2008-11-05       Impact factor: 4.246

Review 10.  The role of anti-inflammatory agents in Parkinson's disease.

Authors:  Edith G McGeer; Patrick L McGeer
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.